5.1.6 Compugen Ltd GenCore version (c) 1993 - 2004 Copyright

sw model using protein search, OM protein 2004, 12:43:42 ω October Run on:

; Search time 57.8571 Seconds (without alignments) 107.438 Million cell updates/sec Pra Pra

-ourse US-10-013-036A-10 85 1 FKXWXFXXPGXAKXGXFNXYKX score: Title: Perfect so Sequence:

Gapext BLOSUM62 Gapop 10.0 , table: Scoring

O .5

residues 282547505 1586107 seqs, Searched

1586107 hits satisfying chosen parameters: O F Total number

2000000000 seg length: seg length: Minimum DB Maximum DB

Post-processing: Minimum Match 0% Maximum Match 100% Listing first 45 summaries

Database

Geneseq_29Jan04:*

geneseqp1980s:*

geneseqp2000s:*

geneseqp2001s:*

geneseqp2002s:*

geneseqp2003as:*

geneseqp2003as:*

٧.

ve a printed, Pred. No. is the number of results predicted by chance to hav score greater than or equal to the score of the result being and is derived by analysis of the total score distribution.

SUMMARIES

	Description	b81191 Stre	y77448 Stre	y77447 Stre	b81190 Strepto	y77449 Derivat	b81192 Der	71733	371734 S.	971732 S.	11737	71736 S.	71735 S.	72549	90343 S.	71726 S.	71730	71728	71731	71729	ap91366 Se	ar85080 H		ap98498 Sequen	ar37315 EpiA pro	Amino a
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1																									. •
	TD	AAB8119	4	7744	ወ	44	8119	7173	7173	71.73	ABG71737	7173	7173	7254	9034	$^{\circ}$	37173	37172	G7173	G7172	136	508	ABG72550	9849	731	321
	<u>m</u> 1	4	m	m	4	ო	な	9	9	9	ø	φ	G	9	~	Q	9	9	9	Q	ч	~	w	H	N	N
	Length D	21	.22	22	22	25	25	22	22	22	22	22	22	62	63	63	22	22	22	22	22	47	51	52	52	52
O H	д; :	83.5	~	ά.	83.5	~		m	78.8	75.3	74.1	Α.	ς,	72.9		CI.	71.8	ω	68.2	∞	N	N	N	0	52.9	N
	Score	71	71	71	71	71	71	67	67	64	63	62	62	62	62	62	61	59	28	58	45	4. N	45	45	45	45
Result	No.	 	(7)	ო	4,	Ŋ	Q	7	ω	σı	10	11	4	13	14	1	16	17	18	<u>ң</u>	20	5 .	22	23	. 24	25

ы	덛		υ	Ω	>	Ę		Ų	υ	Ü	מ	>	E	ų	>		-1	۲H	o	
S. epide	S. galli	Sednen	Staphyl	Photorh	Bovine C	Human po	MUREG-	Staphylo	Staphylo	Staphylo	E. coli	Bovine	Z		Human no	Human po	Human po	Drosophi	Human pr	
Aay43430	b1103	0405	m71112	n70476	60073	870	r34536	ar45020	b6734	bb7624	g9885	r7399	Abg22519	346	2072	58	P8 983	9169	47	
															•					
43	AAB11031	40	11	7	7	AA012870	ñ	22	34	4	9885	σ		AAY43460	N	55	983	916	47	
				9					4	S	4	α	4	~	4	4	ம	4,	4	
52	21	22	47	519	7	N	~	4,	4	4	Н	ന	822	4	98	m	4,	258	CA.	
٠ دا			т Т	N.	Ξ.	ન	1	-	-	+-1		~~	41.2	\circ	\circ	0	40.0	0	40.0	
45	43	43	41	36	in N	n n	n S	35	35	35	35	35	35	34	34	34	34	ω 4.	34	
26	27	28	29	30	31	35	: e	3.4	ខា	36	37	38	9	40	4	, 42,	43	なな	45	

ALIGNMENTS

RESU	RESULT 1
AABE	AAB81191 In Amboliot standard, nentide, 21 aa
ξ	Amboliji acamaara, Peperas, 2: iii:
AC	AAB81191;
×	
DŢ	18-JUL-2001 (first entry)
××	
DE	Streptococcus mutans mutacin B-Ny266.
×	
ž	Mutacin; B-Ny266; type A lantibiotic; bactericide; gram-pos
Š	antibacterial; growth inhibition; post-translational modifi
X X	biopreservative; anticaries agent; disinfectant; lanthionin
XX	
SO	Streptococcus mutans.
×	
Ţ	Key Location/Oualifiers

sitive; ication; ne.

HH	Key	Location/Qualifiers
ъŢ	Modified-site	
FT		/note= "Residues 3 and 7 combine to form lanthionine"
FT	Modified-site	ın
FT		/note= "2,3-didehydroalanine"
ΡŢ	Modified-site	
гŢ		/note= "Residues 8 and 11 combine to form beta-methyl
FT		lanthionine"
FT	Modified-site	8
FT		/label= Abu
F4 F4	Modified-site	14
Ħ		<pre>/note= "(2)-2,3-didehydrobutyrine"</pre>
[H [14	Modified-site	
FŦ		/note= "Residues 16 and 21 combine to form lanthionine"
FT	Modified-site	
FT		/note= "Residues 19 and 21 combine to form Dha-S-Ala
БŢ		(AVI)"
FL	Modified-site	19
FT		/note= "2,3-didehydroalanine"
×		
Md	US6218362-B1.	
×		
D.	17-APR-2001.	
አአ ₽ ፑ	08-SEP-1997;	97US-09924952.
XX		7
PR	08-SEP-1997;	97US-00924952.
XX &	(UYLA-) UNIV L	LAVAL.
XX Id	Lavoie M. Mota	Mota-Meira M, Lacroix C, Lapointe G;
X	-	

97CA-02209893

Novel mutacin B-Ny266 polypeptide having a spectrum of antibacterial activity, useful for combating bacteria and for treating bacterial infections.

2001-289846/30.

WPI;

Claim 3; Fig 1; 11pp; English

and WPI;

22 AA; Sequence

Gaps ö Length 22; Indels Score 71; DB 3; Pred. No. 4.2e-07; Mismatches **;** B3.5%; Similarity 80.0%; 16; Conservative Swery Match Best Local S Best Loc Matches

ö

20 FKAWXFAXPGAAKXGAFNXY FKXWXFXXPGXAKXGXFNXY δ q

AAY77447 standard; peptide; RESULT AAY77

AA

22

(revised)) (first(entry) 12-SEP-2003 22-MAY-2,000

-methy]

AAY77447;

proB-Ny266 mutans mutacin precusor, ococcus Strept

onal post-translati; antibacterial h, precursor, lantibiotic type A; l focin, Gram-positive; bactericide; |inhibition. bactert growyh Mutaci

Ny266 mutans; str. Streptococcus

CA2209893-A1.

08-MAR-1999

This sequence represents mutacin B-Ny266, which is post-translationally modified from a precursor peptide, pro-B-Ny266 (AAY77447). Mutacin B-Ny266 is a 2.27 kD bacteriocin isolated from Streptococcus mutans strain Ny266. It is a type A lantibiotic, containing lanthionine and beta-methyl anthionine bridges, and unsaturated amino acids such as 2,3-didehydrobutyrine and 2-aminobutyric acid (Abu). However, its amino acid sequence differs substantially from those of other type A lantibiotics. Mutacin B-Ny266 is structurally related to the lantibiotics epidermin and agallidermin, and has potent antibacterial cardina positive bacteria tesfed, including Neisseral subflava, Clostridium for the Gram-negative bacterium Flavobacterium capsulatum, the growth of the Gram-negative bacterium Flavobacterium capsulatum, indicating that the activity of mutacin B-Ny266 is not limited to Gram-positive strains. The mutacin B-Ny266 is not limited to Gram-positive strains. The mutacin B-Ny266 is not limited to Gram-positive strains. The mutacin B-Ny266 is not limited to Gram-positive strains. The mutacin B-Ny266 is not limited to Gram-positive and/or stabiliser for cosmetics, in personal hygiene products, as an anticaries agent (e.g. in toothpastes and mouth washes), as a disinfectant cleanser (e.g., in an inti-acne composition), in a godstuffs for prayenting spoilage (e.g., meats, dairy products, beer, and wine), and as a selective agent in culture media. (Updated on 12-SEP-Novel mutacin isolated from Streptococcus mutans designated useful for treating Gram positive bacterial infections. Lavoie M; Ö Lapointe 42pp; English 97CA-02209893 Σ Mota-Meira 2000-171582/16 1; Fig UNIV 08-SEP-1997; ũ m .. (UYLA-) Lacroix Claim

.rag -036a-10

B-Ny266

This sequence represents mutacin B-Ny266, which is post-translationally modified from a precursor peptide, pro-B-Ny266 (AAB81190). Mutacin B-Ny266 is a type A lantibiotic isolated from Streptococcus mutans. Mutacin is related to Epidermin and Gallidermin (other lantibiotics), and contains lanthionine and beta-methyl lanthionine residues. B-Ny266 has potent antibacterial activity against 98% of the S. mutans strains tested, and also exhibits antibacterial against gram positive bacterial including Actinobacilli, Actinomyces such as A.viscous, Bacillus sp., Enterococci, Clostridium sp., Corynebacterium diphteriae, Listeria monocytogenes, Mycobacterium phlei, Neisseria, Propionobacterium acnes, Staphylococcus and Streptococcus, and Gram-negative strains, e.g. Staphylococcus and Streptococcus, and Gram-negative strains, e.g. Staphylococcus and streptococcus, in personal hygiene products, as an anticaries agent e.g. in toothpastes and mouth washes, as a disinfectant cleanser, e.g. in an anti-acne composition, in foodstuffs for preventing spellage, e.g. meats, dairy products, beer and wine, and as a selective

ö

21;

Length

Indels

4

Score 71; DB 4; Pred. No. 4e-07; ; Mismatches

83.5%;

eats, d media

r e

spoilage, agent in c

21 AA

Sequence

0

Conservative

Similarity 16; Conser

Query Match Best Local S Matches 16

FKAWXFAXPGAAKXGAFNXY PG BRX FROWX FOX

d d

င်

RESULT

AAY77448 standard; peptide; 22

RESULT 2 AAY77448

AAY77448;

entry) (revised) (first ent 12-SEP-2003 22-MAY-2000

Streptococcus mutans mutacin B-Ny266.

ibiotic type A; post-translational modification; Gram-positive; bactericide; antibacterial; Mutacin; lantibiotic bacteriocin; Gramgrowth inhibition.

Streptococcus mutans; str. Ny266.

form lant form to 40 7 combine "2,3-didehydroalanine" 3. ./ /note= "Residues 3 and Location/Qualifiers note= Key Modified-site Modified-site Modified-site

"(2)-2,3-didehydrobutyrine* note= "Residues 8 and 11 combine anthionine" ...11 /note= lant note= Modified-site Modified-site

and 21 combine to form lanthionine" combine to form Dh and 21 .21 e= "Residues 16 (19 19. .22 /note= "Residues 1 (AVI)" /note= 19. .22 Modified-site

a-S-Ala

CA2209893-A1

200

08-MAR-1999